1例利妥昔单抗过敏患者成功脱敏。

IF 0.7 Q4 IMMUNOLOGY

Case Reports in Immunology Pub Date : 2015-01-01 Epub Date: 2015-01-20 DOI:10.1155/2015/524507

Pinar Ataca, Erden Atilla, Resat Kendir, Sevim Bavbek, Muhit Ozcan

{"title":"1例利妥昔单抗过敏患者成功脱敏。","authors":"Pinar Ataca, Erden Atilla, Resat Kendir, Sevim Bavbek, Muhit Ozcan","doi":"10.1155/2015/524507","DOIUrl":null,"url":null,"abstract":"Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid drug desensitization method in patients who are allergic to rituximab. We report a low grade B cell non-Hodgkin lymphoma patient with rituximab hypersensitivity successfully treated with rapid drug desensitization. In experienced centers, drug desensitization is a novel modality to break through in case of hypersensitivity that should be considered. ","PeriodicalId":42865,"journal":{"name":"Case Reports in Immunology","volume":"2015 ","pages":"524507"},"PeriodicalIF":0.7000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/524507","citationCount":"14","resultStr":"{\"title\":\"Successful desensitization of a patient with rituximab hypersensitivity.\",\"authors\":\"Pinar Ataca, Erden Atilla, Resat Kendir, Sevim Bavbek, Muhit Ozcan\",\"doi\":\"10.1155/2015/524507\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid drug desensitization method in patients who are allergic to rituximab. We report a low grade B cell non-Hodgkin lymphoma patient with rituximab hypersensitivity successfully treated with rapid drug desensitization. In experienced centers, drug desensitization is a novel modality to break through in case of hypersensitivity that should be considered. \",\"PeriodicalId\":42865,\"journal\":{\"name\":\"Case Reports in Immunology\",\"volume\":\"2015 \",\"pages\":\"524507\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2015-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2015/524507\",\"citationCount\":\"14\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2015/524507\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2015/1/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2015/524507","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/1/20 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 14

摘要

利妥昔单抗是一种靶向B细胞中CD20的单克隆抗体，用于治疗CD20阳性的肿瘤和血液恶性肿瘤。利妥昔单抗在输注期间引起过敏反应。对利妥昔单抗过敏的患者可采用快速药物脱敏方法防止治疗延误或高效率药物的丢失。我们报告一例低级别B细胞非霍奇金淋巴瘤患者利妥昔单抗超敏反应成功治疗快速药物脱敏。在经验丰富的中心，药物脱敏是一种新的模式，以突破的情况下，应考虑过敏。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Successful desensitization of a patient with rituximab hypersensitivity.

Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid drug desensitization method in patients who are allergic to rituximab. We report a low grade B cell non-Hodgkin lymphoma patient with rituximab hypersensitivity successfully treated with rapid drug desensitization. In experienced centers, drug desensitization is a novel modality to break through in case of hypersensitivity that should be considered.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Case Reports in Immunology IMMUNOLOGY-

CiteScore

1.90

自引率

0.00%

发文量

审稿时长

15 weeks

期刊介绍： Case Reports in Immunology is a peer-reviewed, Open Access journal that publishes case reports and case series related to allergies, immunodeficiencies, autoimmune diseases, immune disorders, cancer immunology and transplantation immunology.